Hip replacement judgments in 2016 cost the global brand more than $1.5B with more judgments pending.
Hip replacement issues have left many people in pain. Johnson and Johnson lost 6 out of 7 product liability claims in 2016. The cases have been noted as the largest jury verdicts over product defect claims in America.
Beyond these judgments, there are tens of thousands of potential cases against the brand. Potential legal issues are related to hip replacements, pelvic mesh, and baby powder among other products.
Bloomberg outlined Johnson & Johnson’s legal failures like so:
Hip implant, Dallas: for $1 billion
Hip implant, Dallas: $502 million
Talc, St. Louis: $72 million
Risperdal, Philadelphia: $70 million
Talc, St. Louis: $70 million
Talc, St. Louis: $55 million
2017, has not left the brand in the clear, hip replacement, baby powder, and other big settlements will continue to cost the company.
If you have suffered pain or suffering due a faulty Johnson & Johnson hip replacement product, you could be entitled to compensation.
The Zimmer Biomet shoulder device is facing a class 1 recall from the FDA.
Due to a “higher fracture rate than stated” the Food and Drug Administration (FDA) has issued a class one recall of the Zimmer Biomet reverse shoulder device. Such recalls are reserved for products that “will cause serious adverse health consequences or death.”
This medical device recall, the most serious recall category, was issued this February. The recall reportedly included 3,662 devices.
Risks included a need for revision surgery. According to experts, such surgeries might lead to permanent loss of shoulder function, infection and even death.”
Patients that may have received the Zimmer Biomet device may be entitled to compensation for their pain and/or suffering. For more information about filing a claim through Medical Claim Legal, complete a claim form at this link.
Lupron was injected in thousands of women in an effort to inhibit puberty or increase height.
More than 10,000 adverse event reports have been filed with the FDA based on the experiences of women who’ve taken Lupron. The reports describe a variety of symptoms experienced by those who took the drug to grow taller or delay puberty.
Lupron, currently manufactured by AbbVie, is an injection designed to reduce testosterone in men or estrogen in women. The drug is also approved for use by men with prostate cancer.
The experiences of the women that used the drugs are varied but complex. Many women reported experiencing symptoms and conditions linked to older, even elderly people. According to the FDA reports:
A 20-year-old was diagnosed with osteopenia, a thinning of the bones. A 26-year-old in Massachusetts needed a total hip replacement. One 25-year-old woman from Pennsylvania has osteoporosis and a cracked spine. In Wisconsin, another woman in her 20’s has chronic pain and degenerative disc disease.
Other women described depression and anxiety.
Additionally, the FDA is reviewing deadly seizures caused by the use of Lupron and similar drugs.
The drug has had success in the marketplace. In 2015, the drug-maker reportedly brought in $826 million in sales.
On Friday, a federal judge denied the corporation’s bid to overturn a 2015 state ruling to label it as a cancer risk.
The main criticism is Roundup’s main ingredient. The popular weed-killer includes Glyphosate, a chemical which was originally touted as a way to kill weeds while leaving crops and plants intact.
The U.S. Environmental Protection Agency, says it has ‘low toxicity.’ The agency considers Glyphosate safe when used correctly.
However, under California Proposition 65 label requirements in California, businesses are required to notify Californians about significant amounts of chemicals in the products that they purchase.
Chemicals that require labeling include ingredients or additives in pesticides, common household products, food, drugs, dyes, or solvents.
California regulators are waiting for the lawsuit to be resolved before deciding whether to require warnings, said Sam Delson, a spokesman for the state Office of Environmental Health Hazard Assessment.
“Software is never perfect and all systems still will have these flaws,” says Joshua Corman, director of the Cyber Statecraft Initiative at the Atlantic Council and an expert on medical device security. “The question is how gracefully and collaboratively and quickly and safely can we respond to these flaws.”
In late 2016, there were reports that the Merlin@home transmitter used in monitoring certain St. Jude Medical implant devices could be hacked. These hacks could lead to deadly consequences for the patient.
Ever since the US government and St. Jude confirmed the one flaw, the VA has been “taking steps to be sure all our patients and providers are aware of this issue and take appropriate actions to be sure that all our patients get the update for their monitor,” said Merritt Raitt, acting director of the VA National Cardiac Device Surveillance Program.
The more a person breathes in tiny asbestos particles, the more likely that individual will develop a large variety of lung and breathing complications.
Asbestos was introduced to the construction industry over 100 years ago. It was widely considered the standard for strengthening building materials in the construction of buildings.
The dangers of inhaling asbestos fibers began to surface around 1980. It does not take extreme exposure to asbestos for it to be dangerous. Most victims of asbestos exposure and asbestosis have worked or lived in an environment where there is asbestos in the building or home.
These effects range from wheezing and shortness of breath to mesothelioma and lung cancer. Regardless of your condition, Medical Claim Legal can help you obtain compensation.
There are a large number of lawsuits involving asbestos exposure and asbestosis. Do not let your case get passed over. Medical Claim Legal will connect you with a lawyer who is experienced and successful in the asbestos lawsuit field. To get the compensation that may be owed to you, contact Medical Claim Legal today.
MedicalClaimLegal, simplifying the process for Asbestos Exposure and Asbestosis compensation
The company has agreed to pay a $150 million fine after they allegedly failed to detect and report suspicious orders of prescription pain pills, according to federal prosecutors. This has arguably led to the growing heroin crisis.
For example, more than 1.6 million orders for controlled substances were filled by McKesson in Colorado between June 2008 through May 2013. However, just 16 of them from a single customer as suspicious, the Justice Department said.
In a statement from the White House last summer, federal fears related to pain killer and opioid addictions were made clear:
“President [Obama] has made [it] clear that addressing this epidemic is a priority for his Administration. While Federal agencies have been using their authority to take every available action they can, Congress needs to take action on what is most urgently needed now – additional funding to make lifesaving treatment available to everyone who seeks it. The President has called for $1.1 billion in new funding to help Americans who want treatment get it wherever they live.”
McKesson, the nation’s largest drug distributor, was accused of failing to create an effective system to detect suspicious pharmacy orders. This was argued to be a violation of the Controlled Substances Act.
In 2008, McKesson agreed to a $13.25 million civil penalty for actions including failing to report suspicious sales of their drugs on “internet pharmacies.”
In a statement, McKesson said it settled “in the interest of moving beyond disagreements about whether McKesson was complying with the controlled substance regulations … and to instead focus on the company’s partnership with regulators and others to help stem the opioid epidemic in this country.”
Lawsuit claims Coca-Cola misled consumers on sugary soda health risks.
The consumer-advocacy group, Center for Science in the Public Interest (CSPI) asserts that Coca-Cola has misled consumers about the health risks of sugary drinks such as soda.
In 2015, it was revealed that the corporate giant had heavily funded and been involved in the operation of the research group Global Energy Balance Network. Coca-Cola aimed to help establish the group as a “reputable scientific source to counter “public health extremists.” The company has starkly tried to avoid claims that their products are unhealthy.
It is based on these findings that the lawsuit claims that, “for years, [the] defendants have engaged in a pattern of deception to mislead and confuse the public (and governmental entities that bear responsibility for the public health) about the scientific consensus that consumption of sugar-sweetened beverages is linked to obesity, type 2 diabetes, and cardiovascular disease.”
The industry group, American Beverage Association (ABA) is the co-defendant in the lawsuit. The ABA continues to argue that obesity is a “complex condition.” Further asserting that as obesity and diabetes rates continue to rise, that soda consumption is dropping.
CSPI wants the ABA and Coca-Cola to make some changes. They want marketing to disclose the health risks of sugary drinks, while stopping ads directed at children. They also want the groups to disclose file “indicating the potential health implications.” Plus, the CSPI would like for Coca-Cola and the ABA to fund a public health campaign.
The ABA said in a statement that “America’s beverage companies know we have an important role to play in addressing our nation’s health challenges. That’s why we’re engaging with health groups and community organizations to drive a reduction in the sugar and calories Americans get from beverages.”
Coca-Cola has called the suit “legally and factually meritless.”
A lawsuit accusing Medtronics of covering up negative side effects of its Infuse bone graft has been revived by an appeals court.
A lawsuit accusing Medtronic of misleading shareholders by concealing the adverse effects of its Infuse bone graft, has been revived by the The 8th U.S. Circuit Court of Appeals in St. Paul, Minnesota.
The Infuse bone graft has been used in more than 1 million surgeries. In 2002, the FDA approved the Infuse bone graft for use in specific types of spinal fusion surgeries. The Infuse bone grafts variety are“synthetic, concentrated proteins…mixed with collagen from cows and injected into the spine to alleviate pain.”
The Spine Journal found, in 2011, that the risks of the product had been understated by medical professionals.
In 2012, the U.S. Senate Finance Committee stated that Medtronic, Inc., the manufacturer of the Infuse bone graft, had paid doctors hundreds of millions of dollars to write favorable articles and manipulate studies on the popular product.
In 2013, Medtronic shareholders sued the company claiming that the company’s stock had been inflated due to these unethical activities. As the truth about the product emerged, they have alleged hundreds of millions of dollars in losses.
In 2014, Medtronic agreed to settle its Infuse bone graft lawsuit for $22 million that involves 950 people. Around 2,300 surgeons had used Medtronic products in the US prior to any serious side effects being reported.
An earlier decision in the case judged that shareholders had waited too long before seeking legal action. As 2016 came to a close an appeals court found that the case could still be brought forward.
The case will now be returned to the lower court for further proceedings.